Advanced search
1 file | 132.86 KB

Menopausal hormone therapy and pancreatic cancer risk in women : a population-based matched cohort study

Author
Organization
Abstract
Background: The role of menopausal hormone therapy (MHT) in the development of pancreatic cancer is inconclusive owing to small studies and lack of proper study design. Methods: This population-based matched cohort study included all Swedish women who used systemic MHT between 1 July 2005 and 31 December 2012. For each user of MHT, three never-users of MHT were randomly selected, matched for childbirth, history of thromboembolic events, and previous hysterectomy, as well as for year of birth, diabetes, obesity, and smoking- or alcohol-related disorders. Multivariable conditional logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for the association between MHT use and pancreatic cancer. The effect of MHT duration on pancreatic cancer development was calculated using multivariable Poisson regression. Results: There were 290,186 ever-users of MHT and 870,165 matched never-users. During the follow-up, 311 (0.0011%) ever-users of MHT and 1220 (0.0014) never-users developed pancreatic cancer. In a multivariable adjusted model, ever-users had a 23% reduced risk (OR 0.77; 95% CI: 0.68-0.87) of pancreatic cancer. This risk decreased by 35% (incidence rate ratio (IRR) 0.65; 95% CI: 0.33-1.27) in women who used MHT 1-2 years and by 60% (IRR 0.40; 95% CI: 0.18-0.88) in women who used MHT3 years compared to women with <1 year of MHT use. The type of MHT did not change the results. Conclusion: Systemic MHT use might reduce the risk of pancreatic cancer.
Keywords
REPRODUCTIVE FACTORS, ESTROGEN-RECEPTOR, UNITED-STATES, CELLS, 2-METHOXYESTRADIOL, PARITY, Menopausal hormone therapy, pancreatic cancer, etiology, epidemiology, population-based study

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 132.86 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Sadr-Azodi, Omid, Peter Konings, and Nele Brusselaers. 2017. “Menopausal Hormone Therapy and Pancreatic Cancer Risk in Women : a Population-based Matched Cohort Study.” United European Gastroenterology Journal 5 (8): 1123–1128.
APA
Sadr-Azodi, O., Konings, P., & Brusselaers, N. (2017). Menopausal hormone therapy and pancreatic cancer risk in women : a population-based matched cohort study. UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 5(8), 1123–1128.
Vancouver
1.
Sadr-Azodi O, Konings P, Brusselaers N. Menopausal hormone therapy and pancreatic cancer risk in women : a population-based matched cohort study. UNITED EUROPEAN GASTROENTEROLOGY JOURNAL. 2017;5(8):1123–8.
MLA
Sadr-Azodi, Omid, Peter Konings, and Nele Brusselaers. “Menopausal Hormone Therapy and Pancreatic Cancer Risk in Women : a Population-based Matched Cohort Study.” UNITED EUROPEAN GASTROENTEROLOGY JOURNAL 5.8 (2017): 1123–1128. Print.
@article{8548967,
  abstract     = {Background: The role of menopausal hormone therapy (MHT) in the development of pancreatic cancer is inconclusive owing to small studies and lack of proper study design. 
Methods: This population-based matched cohort study included all Swedish women who used systemic MHT between 1 July 2005 and 31 December 2012. For each user of MHT, three never-users of MHT were randomly selected, matched for childbirth, history of thromboembolic events, and previous hysterectomy, as well as for year of birth, diabetes, obesity, and smoking- or alcohol-related disorders. Multivariable conditional logistic regression was used to calculate odds ratios (ORs) and 95\% confidence intervals (CIs) for the association between MHT use and pancreatic cancer. The effect of MHT duration on pancreatic cancer development was calculated using multivariable Poisson regression. 
Results: There were 290,186 ever-users of MHT and 870,165 matched never-users. During the follow-up, 311 (0.0011\%) ever-users of MHT and 1220 (0.0014) never-users developed pancreatic cancer. In a multivariable adjusted model, ever-users had a 23\% reduced risk (OR 0.77; 95\% CI: 0.68-0.87) of pancreatic cancer. This risk decreased by 35\% (incidence rate ratio (IRR) 0.65; 95\% CI: 0.33-1.27) in women who used MHT 1-2 years and by 60\% (IRR 0.40; 95\% CI: 0.18-0.88) in women who used MHT3 years compared to women with {\textlangle}1 year of MHT use. The type of MHT did not change the results. 
Conclusion: Systemic MHT use might reduce the risk of pancreatic cancer.},
  author       = {Sadr-Azodi, Omid and Konings, Peter and Brusselaers, Nele},
  issn         = {2050-6406},
  journal      = {UNITED EUROPEAN GASTROENTEROLOGY JOURNAL},
  keyword      = {REPRODUCTIVE FACTORS,ESTROGEN-RECEPTOR,UNITED-STATES,CELLS,2-METHOXYESTRADIOL,PARITY,Menopausal hormone therapy,pancreatic cancer,etiology,epidemiology,population-based study},
  language     = {eng},
  number       = {8},
  pages        = {1123--1128},
  title        = {Menopausal hormone therapy and pancreatic cancer risk in women : a population-based matched cohort study},
  url          = {http://dx.doi.org/10.1177/2050640617702060},
  volume       = {5},
  year         = {2017},
}

Altmetric
View in Altmetric
Web of Science
Times cited: